CaptureSelect™ IgG-CH1 Affinity Matrix has been specifically designed for the purification of recombinant human Fab fragments and IgGs, recognizing all IgG subclasses (1, 2, 3 and 4) independent of the light chain subclass (Kappa/Lambda).

Features of this affinity matrix include:

• Platform approach for purification of IgGs and their Fab fragments
• No co-purification of overexpressed free lights chains due to heavy chain binding
• Excellent scalability
• Non-animal-derived

CaptureSelect™ IgG-CH1 Affinity Matrix purifies IgG, Fab, and Fab2 fragments directly from complex source materials in a single step with high purity and yield.

Free of animal components
CaptureSelect products contain affinity ligands based on recombinant single-domain antibody fragments (VHH) created by a proprietary technology. The VHH affinity ligand is a 12 to 15 kDa fragment comprising the three complementarity-determining regions (CDRs) that form the antigen-binding domain, efficiently produced in the yeast Saccharomyces cerevisiae by a production process free of any animal components (Animal Origin-Free).

Main Characteristics:

Matrix: agarose-based, aldehyde-activated
Average particle size: 65 ± 10 µm
Ligand: CaptureSelect™ IgG-CH1 affinity ligand
Ligand coupling method: aldehyde coupling via NH₂ residues of the ligand
Binding capacity: 25–30 g IgG/L resin depending on flow rate, column height and contact time
Elution conditions: 20 mM citric acid, 150 mM NaCl, pH 3.5
Flow characteristics: 50–200 cm/h (up to 2 bar)
Formulation buffer: 20%(v/v) ethanol